S100A9 and neoplasm: Tasquinimod, a novel oral quinoline-3-carboxamide derivative, was shown to have multiple effects on the tumour microenvironment [75] including possible binding to S100A9 protein which leads to the inhibition of interaction between S100A9 and receptors such as RAGE and TLR4.